Decipher Labs (524752)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Book value still positive at ₹10.28 per share, providing a floor if assets are honestly valued
• Tiny market cap (₹17 Cr) leaves potential for a niche pharma turnaround if operational execution improves
• Piotroski F-Score of 5/9 suggests modest financial health, not outright distress
• Reported profit growth of 8.47% (though from a loss-making base) hints at cost-control efforts

Concerns

• Sales collapsed 44.66%, indicating severe demand or regulatory setback
• ROE and ROCE are deeply negative, proving capital destruction
• Latest quarter still lost ₹1 Cr on ₹3 Cr sales, no path to breakeven visible
• No dividend, no promoter holding disclosure, and negligible market cap—poor governance and liquidity risks

AI Analysis

This is a tiny pharmaceutical shell, a ₹17 crore market cap with a stock price of ₹17.01 against a book value of ₹10.28. I am paying a 65% premium to tangible assets for a business that loses money. Return on equity is negative 2.77%, and return on capital employed is even worse at negative 4.67%. The latest quarter shows sales of just ₹3 crore and a net loss of ₹1 crore. Sales have collapsed by 44.66% year-on-year—this is not a temporary blip; it is a business in distress. The reported 8.47% profit growth is meaningless when absolute profit is still negative. There is no moat, no pricing power, no evidence of competitive strength. Debt/equity is not reported, which itself is a red flag for minority shareholders—lack of transparency. With zero dividend yield and promoter holding unavailable, I cannot assess alignment of interests. Piotroski F-score of 5/9 is mediocre, not a strong catalyst. At ₹17, the market is already celebrating the 52-week high, but the fundamentals do not justify optimism. This is not an asset play because I am paying above book for a deteriorating earnings base. It is not a stalwart or grower—sales are shrinking. The only bull case is a turnaround, but there is no data showing a credible recovery plan. I would need a margin of safety, a clear path to profitability, and evidence that management is capital-allocation disciplined. None of these exist today. I would pass. In Graham's words, 'The investor's chief problem—and even his worst enemy—is likely to be himself.' Avoid the temptation to speculate in a story without numbers.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer